US Stock MarketDetailed Quotes

CVKD Cadrenal Therapeutics

Watchlist
  • 0.430
  • +0.008+1.92%
Close Apr 18 16:00 ET
  • 0.428
  • -0.002-0.42%
Post 19:03 ET
6.88MMarket Cap-669P/E (TTM)

About Cadrenal Therapeutics Company

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focused on developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang Pham and Matthew Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Company Profile

SymbolCVKD
Company NameCadrenal Therapeutics
Listing DateJan 20, 2023
Issue Price5.00
Founded2022
CEOMr. Quang X. Pham
MarketNASDAQ
Employees4
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address822 A1A North,Suite 306
CityPonte Vedra Beach
ProvinceFlorida
CountryUnited States of America
Zip Code32082
Phone1-904-300-0701
Websitehttp://www.cadrenal.com

Company Executives

  • Name
  • Position
  • Salary
  • Quang X. Pham
  • Chairman of the Board and Chief Executive Officer
  • 816.22K
  • Matthew K. Szot
  • Chief Financial Officer and Principal Accounting Officer
  • 359.61K
  • Dr. Douglas W. Losordo, M.D.
  • Chief Medical Officer
  • 648.56K
  • Jeffrey Cole
  • Chief Operating Officer
  • --
  • Robert Lisicki
  • Director
  • --
  • John Raymond Murphy
  • Independent Director
  • 225.00K
  • Dr. Glynn Wilson,PhD
  • Independent Director
  • 149.65K
  • Steven Zelenkofske
  • Independent Director
  • 118.75K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg